Enanta Pharmaceuticals to Showcase Promising RSV Drug Data at ESCMID Global 2026
Event summary
- Enanta Pharmaceuticals will present data on zelicapavir, an oral, once-daily N-protein inhibitor for RSV, at ESCMID Global 2026.
- Phase 2b study results show a week improvement in symptom resolution and lower hospitalization rates in high-risk adults.
- New data confirms zelicapavir’s high barrier against antiviral resistance in pediatric patients.
- Presentations scheduled for April 18, 2026, in Munich, Germany.
The big picture
Enanta Pharmaceuticals is positioning zelicapavir as a potential leader in RSV treatment, leveraging its chemistry-driven approach. The data presented at ESCMID Global 2026 could solidify its standing in the antiviral space, particularly as RSV remains a significant public health challenge. The company's history with AbbVie's HCV treatments underscores its capability in developing small molecule drugs, but the RSV market will require strategic differentiation to compete with established and emerging therapies.
What we're watching
- Clinical Efficacy
- How the Phase 2b results will influence the design and timing of Phase 3 trials for zelicapavir.
- Regulatory Pathway
- Whether the data presented will accelerate regulatory discussions with health authorities.
- Market Positioning
- The pace at which Enanta can differentiate zelicapavir in the competitive RSV treatment landscape.
Related topics